.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Novartis
Merck
Citi
Daiichi Sankyo
Cantor Fitzgerald
Dow
Deloitte
Mallinckrodt
Farmers Insurance

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title: Combination of atovaquone with proguanil for the treatment of protozoal infections
Abstract:The invention relates to combinations of atovaquone and proguanil, their use in the treatment and propinylaxis of parasitic infections, such as protozoal parasitic infections, e.g. malaria and toxoplasmosis, and infections caused by P.carinii and their use in the manunfacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
Inventor(s): Gutteridge; Winston Edward (Beckenham, GB), Hutchinson; David Brian Ashton (Beckenham, GB), Latter; Victoria Susan (Beckenham, GB), Pudney; Mary (Beckenham, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/962,273
Patent Claim Types:
see list of patent claims
Use; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9224739Nov 26, 1992

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKesson
US Army
Accenture
McKinsey
Chubb
Farmers Insurance
Johnson and Johnson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot